RESUMEN
STERIS and W.L. GORE collaborated on a case study testing the compatibility of a new prefilled syringe plunger design with VHP terminal sterilization. VHP chamber conditions require deep vacuum pulsing, which may represent challenges to prefilled syringe container integrity. The growing industry trend toward VHP sterilization is driven by the FDA search for alternative sterilization methods to EO and the recent publication of a VHP specific process standard. The purpose of the study is to test and report compatibility of the new 0.5 mL GORE IMPROJECT plunger, a silicone free syringe solution for ophthalmic application, with VHP sterilization. Various challenges have been reported when using conventional, siliconized, prefilled syringe systems for intravitreal injections such as subvisible particles, inflammation, silicone floaters, and intraocular pressure increases. The GORE plunger eliminates the need for silicone oil as a lubricant on the plunger and barrel, while meeting strict container closure and terminal sterilization requirements of ophthalmic applications. This case study presents successful results of deep vacuum VHP terminal sterilization process compatibility with the GORE plunger design and material composition. Test results include primary container integrity, stopper off-gassing/ingress, and visual inspection. Principles of VHP vacuum sterilization process, test cycle configuration, and its main parameters are presented.
Asunto(s)
Peróxido de Hidrógeno , Esterilización , Jeringas , Esterilización/métodos , Jeringas/normas , Peróxido de Hidrógeno/química , Diseño de Equipo , Vacio , Volatilización , Embalaje de Medicamentos/normas , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/instrumentación , Tecnología Farmacéutica/normas , Aceites de Silicona/química , Inyecciones Intravítreas/instrumentaciónRESUMEN
In the traditional Chinese medicine(TCM) manufacturing industry, quality control determines the safety, effectiveness, and quality stability of the final product. The traditional quality control method generally carries out sampling off-line testing of drugs after the end of the batch production, which is incomprehensive, and it fails to find the problems in the production process in time. Process analysis technology(PAT) uses process testing, mathematical modeling, data analysis, and other technologies to collect, analyze, feedback, control, and continuously improve the critical quality attributes(CQA) in all aspects of the production of TCM preparations in real time. The application of PAT in the TCM manufacturing industry is one of the research hotspots in recent years, which has the advantages of real-time, systematic, non-destructive, green, and rapid detection for the production quality control of TCM preparations. It can effectively ensure the stability of the quality of TCM preparations, improve production efficiency, and play a key role in the study of the quantity and quality transfer law of TCM. Commonly used PAT includes near-infrared spectroscopy, Raman spectroscopy, online microwave, etc. In addition, the establishment of an online detection model by PAT is the key basic work to realize intelligent manufacturing in TCM production. Obtaining real-time online detection data through PAT and establishing a closed-loop control model on this basis are a key common technical difficulty in the industry. This paper adopted systematic literature analysis to summarize the relevant Chinese and foreign literature, policies and regulations, and production applications, and it introduced the development trend and practical application of PAT, so as to provide references for accelerating the application of PAT in the TCM manufacturing industry, the intelligent transformation and upgrading, and high-quality development of the TCM industry.
Asunto(s)
Medicamentos Herbarios Chinos , Medicina Tradicional China , Control de Calidad , Medicina Tradicional China/normas , Medicamentos Herbarios Chinos/química , Medicamentos Herbarios Chinos/normas , Medicamentos Herbarios Chinos/análisis , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/normas , Industria Farmacéutica/normasRESUMEN
The last decade has seen Advanced Medicines Manufacturing (AMM) progress from isolated product developments to the creation of industry-academic centres of excellence, regulatory innovation progressing leading to new standards, and product commercialisation across multiple product formats. This paper examines these developments focusing on successful applications and strategies presented at the 2023 Symposium of the International Consortium for Advanced Medicines Manufacturing (ICAMM). Despite these exemplar applications, there remain significant challenges to the sector-wide adoption of AMM technologies. Drawing on Symposium delegate expert responses to open-ended questions, our coding-based thematic analysis suggest three primary enablers drive successful adoption of AMM technologies at scale, namely: the ability to leverage pre-competitive collaborations to challenge-based problem solving; information and knowledge sharing through centres of excellence; and the development of AMM specific regulatory standards. Further analysis of expert responses identified the emergence of a 'Platform creation' approach to AMM innovation; characterised by: i) New collaboration modes; ii) Exploration of common product-process platforms for new dosage forms and therapy areas; iii) Development of modular equipment assets that enable scale-out, and offer more decentralized or distributed manufacturing models; iv) Standards based on product-process platform archetypes; v) Implementation strategies where platform-thinking and AMM technologies can significantly reduce timelines between discovery, approval and GMP readiness. We provide a definition of the Platform creation concept for AMM and discuss the requirements for its systematic development.
Asunto(s)
Industria Farmacéutica , Tecnología Farmacéutica , Humanos , Industria Farmacéutica/métodos , Industria Farmacéutica/legislación & jurisprudencia , Preparaciones Farmacéuticas/normas , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/normasRESUMEN
Gemigliptin-Rosuvastatin single-pill combination is a promising therapeutic tool in the effective control of hyperglycemia and hypercholesterolemia. Organic sensors with high quantum yields have profoundly significant applications in the pharmaceutical industry, such as routine quality control of marketed formulations. Herein, the fluorescence sensor, 2-Morpholino-4,6-dimethyl nicotinonitrile 3, (λex; 226 nm, λem; 406 nm), was synthesized with a fluorescence quantum yield of 56.86% and fully characterized in our laboratory. This sensor showed high efficiency for the determination of Gemigliptin (GEM) and Rosuvastatin (RSV) traces through their stoichiometric interactions and simultaneously fractionated by selective solvation. The interaction between the stated analytes and sensor 3 was a quenching effect. Various experimental parameters and the turn-off mechanism were addressed. The adopted approach fulfilled the ICH validation criteria and showed linear satisfactory ranges, 0.2-2 and 0.1-1 µg/mL for GEM and RSV, respectively with nano-limits of detection less than 30 ng/mL for both analytes. The synthesized sensor has been successfully applied for GEM and RSV co-assessment in their synthetic polypill with excellent % recoveries of 98.83 ± 0.86 and 100.19 ± 0.64, respectively. No statistically significant difference between the results of the proposed and reported spectrophotometric methods in terms of the F- and t-tests. Ecological and whiteness appraisals of the proposed study were conducted via three novel approaches: the Greenness Index via Spider Diagram, the Analytical Greenness Metric, and the Red-Green-Blue 12 model. The aforementioned metrics proved the superiority of the adopted approach over the previously published one regarding eco-friendliness and sustainability. Our devised fluorimetric turn-off sensing method showed high sensitivity, selectivity, feasibility, and rapidity with minimal cost and environmental burden over other sophisticated techniques, making it reliable in quality control labs.
Asunto(s)
Piperidonas , Pirimidinas , Control de Calidad , Rosuvastatina Cálcica , Espectrometría de Fluorescencia , Tecnología Farmacéutica , Laboratorios , Combinación de Medicamentos , Industria Farmacéutica/instrumentación , Industria Farmacéutica/métodos , Industria Farmacéutica/normas , Composición de Medicamentos/instrumentación , Composición de Medicamentos/métodos , Composición de Medicamentos/normas , Tecnología Farmacéutica/instrumentación , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/normas , Color , Espectrometría de Fluorescencia/instrumentación , Espectrometría de Fluorescencia/métodos , Espectrometría de Fluorescencia/normas , Formas de DosificaciónRESUMEN
Monitoring product temperature during lyophilization is critical, especially during the process development stage, as the final product may be jeopardized if its process temperature exceeds a threshold value. Also, in-situ temperature monitoring of the product gives the capability of creating an optimized closed-loop lyophilization process. While conventional thermocouples can track product temperature, they are invasive, limited to a single-point measurement, and can significantly alter the freezing and drying behavior of the product in the monitored vial. This work has developed a new methodology that combines non-invasive temperature monitoring and comprehensive modeling. It allows the accurate reconstruction of the complete temperature profile of the product inside the vial during the lyophilization process. The proposed methodology is experimentally validated by combining the sensors' wirelessly collected data with the advanced multiphysics simulations. The flexible wireless multi-point temperature sensing probe is produced using micro-manufacturing techniques and attached outside the vial, allowing for accurate extraction of the product temperature.
Asunto(s)
Desecación , Tecnología Farmacéutica/métodos , Desecación/métodos , Liofilización/métodos , Congelación , Preparaciones Farmacéuticas , Tecnología Farmacéutica/instrumentación , Tecnología Farmacéutica/normas , Temperatura , Termómetros/clasificaciónRESUMEN
BACKGROUND: The stability of a drug or metabolites in biological matrices is an essential part of bioanalytical method validation, but the justification of its sample size (replicates number) is insufficient. The international guidelines differ in recommended sample size to study stability from no recommendation to at least three quality control samples. Testing of three samples may lead to results biased by a single outlier. We aimed to evaluate the optimal sample size for stability testing based on 90% confidence intervals. METHODS: We conducted the experimental, retrospective (264 confidence intervals for the stability of nine drugs during regulatory bioanalytical method validation), and theoretical (mathematical) studies. We generated experimental stability data (40 confidence intervals) for two analytes-tramadol and its major metabolite (O-desmethyl-tramadol)-in two concentrations, two storage conditions, and in five sample sizes (n = 3, 4, 5, 6, or 8). RESULTS: The 90% confidence intervals were wider for low than for high concentrations in 18 out of 20 cases. For n = 5 each stability test passed, and the width of the confidence intervals was below 20%. The results of the retrospective study and the theoretical analysis supported the experimental observations that five or six repetitions ensure that confidence intervals fall within 85-115% acceptance criteria. CONCLUSIONS: Five repetitions are optimal for the assessment of analyte stability. We hope to initiate discussion and stimulate further research on the sample size for stability testing.
Asunto(s)
Monitoreo de Drogas/métodos , Estabilidad de Medicamentos , Tecnología Farmacéutica/métodos , Análisis de Varianza , Cromatografía Liquida , Monitoreo de Drogas/normas , Humanos , Espectrometría de Masas , Modelos Teóricos , Control de Calidad , Estudios Retrospectivos , Tecnología Farmacéutica/normasRESUMEN
The topic of standardization in relation to allergen products has been discussed by allergists, regulators, and manufacturers for a long time. In contrast to synthetic medicinal products, the natural origin of allergen products makes the necessary comparability difficult to achieve. This holds true for both aspects of standardization: Batch-to-batch consistency (or product-specific standardization) and comparability among products from different manufacturers (or cross-product comparability). In this review, we focus on how the United States and the European Union have tackled the topic of allergen product standardization in the past, covering the early joint standardization efforts in the 1970s and 1980s as well as the different paths taken by the two players thereafter until today. So far, these two paths have been based on rather classical immunological methods, including the corresponding benefits like simple feasability. New technologies such as mass spectrometry present an opportunity to redefine the field of allergen standardization in the future.
Asunto(s)
Desensibilización Inmunológica/normas , Guías de Práctica Clínica como Asunto , Control de Calidad , Tecnología Farmacéutica/normas , Alérgenos , Desensibilización Inmunológica/tendencias , Europa (Continente) , Humanos , Tecnología Farmacéutica/tendencias , Estados UnidosRESUMEN
Pharmaceutical nanotechnology research is focused on smart nano-vehicles, which can deliver active pharmaceutical ingredients to enhance their efficacy through any route of administration and in the most varied therapeutical application. The design and development of new nanopharmaceuticals can be very laborious. In recent years, the application of mathematics, statistics and computational tools is emerging as a convenient strategy for this purpose. The application of Quality by Design (QbD) tools has been introduced to guarantee quality for pharmaceutical products and improve translational research from the laboratory bench into applicable therapeutics. In this review, a collection of basic-concept, historical overview and application of QbD in nanomedicine are discussed. A specific focus has been put on Response Surface Methodology and Artificial Neural Network approaches in general terms and their application in the development of nanomedicine to monitor the process parameters obtaining optimized system ensuring its quality profile.
Asunto(s)
Nanotecnología , Vehículos Farmacéuticos , Tecnología Farmacéutica , Benchmarking , Diseño de Fármacos/métodos , Diseño de Fármacos/tendencias , Humanos , Nanotecnología/instrumentación , Nanotecnología/métodos , Nanotecnología/normas , Vehículos Farmacéuticos/síntesis química , Vehículos Farmacéuticos/farmacología , Control de Calidad , Tecnología Farmacéutica/normas , Tecnología Farmacéutica/tendenciasRESUMEN
Recent changes in the pharmaceutical industry have led to significant paradigm shifts in the pharmaceutical quality environment. Globalization of the pharmaceutical industry, increasingly rapid development of novel therapies, and adoption of new manufacturing techniques have presented numerous challenges for the established regulatory framework and quality environment and are impacting the approaches utilized to ensure the quality of pharmaceutical products. Regulators, industry, and standards-setting organizations have begun to recognize the need to rely more on integrated risk-based approaches and to create more nimble and flexible standards to complement these efforts. They also increasingly have recognized that quality needs to be built into systems and processes throughout the lifecycle of the product. Moreover, the recent COVID-19 crisis has emphasized the need to adopt practices that better promote global supply chain resilience. In this paper, the USP Quality Advisory Group explores the various paradigm shifts currently impacting pharmaceutical quality and the approaches that are being taken to adapt to this new environment. Broad adoption of the Analytical Procedure Lifecycle approach, improved data management, and utilization of digital technologies are identified as potential solutions that can help meet the challenges of these quality paradigm shifts. Further discussion and collaboration among stakeholders are needed to pursue these and other solutions that can ensure a continued focus on quality while facilitating pharmaceutical innovation and development.
Asunto(s)
COVID-19/epidemiología , Industria Farmacéutica/normas , Preparaciones Farmacéuticas/provisión & distribución , Preparaciones Farmacéuticas/normas , Farmacopeas como Asunto/normas , Control de Calidad , COVID-19/prevención & control , Industria Farmacéutica/métodos , Humanos , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/normas , Estados Unidos/epidemiologíaRESUMEN
In this paper we present a thorough description of the digital twin development for a continuous pharmaceutical powder blending process in accordance with the Process Analytical Technologies (PAT) and Quality by Design (QbD) guidelines. A low-dosage system of caffeine active pharmaceutical ingredient (API) and dextrose excipient was examined via continuous blending experiments. Near infrared (NIR) spectroscopy-based process analytics were applied; quantitative evaluation of spectra was achieved using multivariate data analysis. The blending system was represented with mechanistic residence time distribution (RTD) models and two types of recurrent artificial neural networks (ANN), experimental datasets were used for model training or fitting and validation. Detailed comparison of the two modelling approaches, the optimization of the model-based digital twin, and efficiency of the soft sensor-based process monitoring is presented through several validating simulations. Both RTD models and nonlinear autoregressive neural networks demonstrated excellent predictive power for the low dosage blending process. RTD models can prove to be more advantageous in industrial development as they are less resource-intensive to develop and prediction accuracy on low concentration levels lacks dependency from the precision of chemometric calibration. Reduced material costs and limited development timeframe render the digital twin an efficient tool in technological development.
Asunto(s)
Química Farmacéutica/métodos , Composición de Medicamentos , Polvos , Tecnología Farmacéutica , Calibración , Ciencia de los Datos , Teoría Funcional de la Densidad , Composición de Medicamentos/métodos , Composición de Medicamentos/normas , Composición de Medicamentos/tendencias , Humanos , Redes Neurales de la Computación , Polvos/análisis , Polvos/química , Polvos/farmacología , Reproducibilidad de los Resultados , Espectroscopía Infrarroja Corta , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/normasRESUMEN
Céline Caillet and co-authors discuss a Collection on use of portable devices for the evaluation of medicine quality and legitimacy.
Asunto(s)
Medicamentos Falsificados/análisis , Contaminación de Medicamentos , Preparaciones Farmacéuticas/análisis , Farmacias , Control de Calidad , Tecnología Farmacéutica/instrumentación , Diseño de Equipo , Humanos , Laos , Preparaciones Farmacéuticas/normas , Farmacias/normas , Reproducibilidad de los Resultados , Tecnología Farmacéutica/normasRESUMEN
In May 2020, the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) published a recommendation report entitled "Recommendation on nonanimal-derived antibodies". In this report, the EURL ECVAM specifically states: "Therefore, taking into consideration the ESAC Opinion on the scientific validity of replacements for animal-derived antibodies, EURL ECVAM recommends that animals should no longer be used for the development and production of antibodies for research, regulatory, diagnostic and therapeutic applications. The provisions of Directive 2010/63/EU should be respected, and EU countries should no longer authorise the development and production of antibodies through animal immunisation, where robust, legitimate scientific justification is lacking." (1). Here, we are providing the American Association of Pharmaceutical Scientists (AAPS) opinion on the EURL ECVAM recommendation report. In brief, there has been a clear and strong progress in reduction of animal use in the drug discovery and development process, including significant reduction of animal use in production of antibody reagents. Yet, it is proposed that more data need to be generated, shared and discussed within the scientific community before a decision to implement the change to non-animal derived antibodies is made.
Asunto(s)
Alternativas al Uso de Animales/normas , Anticuerpos Monoclonales/aislamiento & purificación , Farmacia/normas , Sociedades Farmacéuticas/normas , Tecnología Farmacéutica/normas , Animales , Anticuerpos Monoclonales/genética , Anticuerpos Monoclonales/uso terapéutico , Unión Europea , Políticas , Proteínas Recombinantes/genética , Proteínas Recombinantes/aislamiento & purificación , Proteínas Recombinantes/uso terapéutico , Tecnología Farmacéutica/métodos , Estados UnidosRESUMEN
Pharmaceutical continuous manufacturing is considered as an emerging technology by the regulatory agencies, which have defined a framework guided by an effective quality risk management. With the understanding of process dynamics and the appropriate control strategy, pharmaceutical continuous manufacturing is able to tackle the Quality-by-Design paradigm that paves the way to the future smart manufacturing described by Quality-by-Control. The introduction of soft sensors seems to be a helpful tool to reach smart manufacturing. In fact, soft sensors have the ability to keep the quality attributes of the final drug product as close as possible to their references set by regulatory agencies and to mitigate the undesired events by potentially discard out of specification products. Within this review, challenges related to implementing these technologies are discussed. Then, automation control strategies for pharmaceutical continuous manufacturing are presented and discussed: current control tools such as the proportional integral derivative controllers are compared to advanced control techniques like model predictive control, which holds promise to be an advanced automation concept for pharmaceutical continuous manufacturing. Finally, industrial applications of model predictive control in pharmaceutical continuous manufacturing are outlined. Simulations studies as well as real implementation on pharmaceutical plant are gathered from the control of one single operation unit such as the tablet press to the control of a full direct compaction line. Model predictive control is a key to enable the industrial revolution or Industry 4.0.
Asunto(s)
Automatización , Industria Farmacéutica/normas , Modelos Teóricos , Control de Calidad , Tecnología Farmacéutica/normas , Industria Farmacéutica/métodos , Tecnología Farmacéutica/instrumentación , Tecnología Farmacéutica/métodosRESUMEN
In Japan, the practical application of completely cell-based seasonal influenza vaccines is under consideration. Considering the good correlation between the immunogenicity of egg-based influenza vaccines and the hemagglutinin (HA) content determined by the single radial immunodiffusion (SRD) assay, we determined the potency of the first cell-based quadrivalent vaccine experimentally generated in Japan using the SRD assay in this study. A primary liquid standard (PLS) and reference antigen were generated from the purified vaccine virus, and a sheep antiserum was produced against the HA of the vaccine virus. Since the purity of the PLS affects the reliability of vaccine potency testing, the purification steps are significant. We successfully prepared a purified PLS nearly free of cell debris. The HA content in the PLS was first estimated from the total amount of viral protein and the percentage of HA content determined by SDS-PAGE analysis. The HA content in the reference antigen was calibrated to that in the PLS via the SRD assay. The vaccine potency, that is, the HA content in each vaccine, was finally measured using the corresponding reference antigen. Ultimately, the measured vaccine potency of the monovalent vaccine was similar to that of the quadrivalent vaccine.
Asunto(s)
Glicoproteínas Hemaglutininas del Virus de la Influenza/inmunología , Subtipo H1N1 del Virus de la Influenza A/inmunología , Vacunas contra la Influenza/inmunología , Gripe Humana/inmunología , Estaciones del Año , Tecnología Farmacéutica/métodos , Potencia de la Vacuna , Animales , Anticuerpos Antivirales/inmunología , Perros , Humanos , Sueros Inmunes/inmunología , Vacunas contra la Influenza/normas , Gripe Humana/prevención & control , Gripe Humana/virología , Células de Riñón Canino Madin Darby , Estándares de Referencia , Ovinos , Tecnología Farmacéutica/normasRESUMEN
The research presented here shows QbD implementation for the optimisation of the key process parameters in electrohydrodynamic atomisation (EHDA). Here, the electrosprayed nanoparticles and electrospun fibers consisting of a polymeric matrix and dye. Eight formulations were assessed consisting of 5% w/v of polycaprolactone (PCL) in dichloromethane (DCM) and 5% w/v polyvinylpyrrolidone (PVP) in ethanol. A full factorial DOE was used to assess the various parameters (applied voltage, deposition distance, flow rate). Further particle and fiber analysis using Scanning Electron Microscopy (SEM), Differential Scanning Calorimetry (DSC), Thermogravimetric Analysis (TGA), Fourier Transform Infrared Spectroscopy (FTIR), particle/fiber size distribution. In addition to this in vitro release studied were carried out using fluorescein and Rhodamine B as model dyes and in vitro permeation studies were applied. The results show a significant difference in the morphology of resultant structures as well as a more rapid release profile for the PVP particles and fibers in comparison to the sustained release profiles found with PCL. In vitro drug release studies showed 100% drug release after 7 days for PCL particles and showed 100% drug release within 120 min for PVP particles. The release kinetics and the permeation study showed that the MN successfully pierced the membrane and the electrospun MN coating released a large amount of the loaded drug within 6 h. This study has demonstrated the capability of these robust MNs to encapsulate a diverse range drugs within a polymeric matrix giving rise to the potential of developed personalised medical devices.
Asunto(s)
Microinyecciones/instrumentación , Agujas , Polímeros/química , Investigación Cualitativa , Tecnología Farmacéutica/instrumentación , Liberación de Fármacos , Microinyecciones/normas , Agujas/normas , Poliésteres/química , Poliésteres/normas , Polímeros/normas , Povidona/química , Povidona/normas , Espectroscopía Infrarroja por Transformada de Fourier/métodos , Tecnología Farmacéutica/normasRESUMEN
This study investigates the performance of a sampling interface for monitoring cohesive, flowing powder formulations with Hausner's Ratio and Carr's Index higher than 1.5 and 35%, respectively. The sampler device was operated in combination with near-infrared (NIR) spectroscopy to quantify ibuprofen concentrations between 1.5 and 4.5% w/w. NIR spectra also provided essential information to study the process dynamics within the sampler. The 200 spectra per blend obtained demonstrated a continuous powder flow with no evidence of agglomerates or segregation within the sampler for a blend of 6 kg. A NIR calibration model was optimized to predict independent test blends, delivering root mean square error of predictions and bias under 0.1% w/w. The test blends were within specifications according to the requirements of European Pharmacopeia. Variographic analysis demonstrated that the sampler device may determine low drug concentration in cohesive powder blends, presenting sampling errors below 0.011 (%w/w)2. This analysis also demonstrated that an increase in the blend compressibility leads to a slight rise in sampling errors within the sampler device. The sampler device offers statistical robustness in the evaluation of blend uniformity, providing greater confidence in the quality determination of the cohesive powder blends without significantly affecting its flow properties.
Asunto(s)
Excipientes/análisis , Ibuprofeno/análisis , Espectroscopía Infrarroja Corta , Tecnología Farmacéutica , Celulosa/análisis , Composición de Medicamentos , Excipientes/normas , Ibuprofeno/normas , Lactosa/análisis , Tamaño de la Partícula , Polvos , Control de Calidad , Espectroscopía Infrarroja Corta/normas , Ácidos Esteáricos/análisis , Tecnología Farmacéutica/normasAsunto(s)
Embalaje de Medicamentos , Preparaciones Farmacéuticas/análisis , Tecnología Farmacéutica , COVID-19 , Contaminación de Medicamentos/prevención & control , Seguridad del Paciente , Preparaciones Farmacéuticas/normas , Preparaciones Farmacéuticas/provisión & distribución , Control de Calidad , Medición de Riesgo , Tecnología Farmacéutica/normasRESUMEN
Twin-screw melt granulation (TSMG) is a new alternative method for granulation that offers several advantages over wet and dry granulation methods. TSMG has rapidly gained interest over recent years in the pharmaceutical industry. Since it is an inherently continuous process with controlled temperature and shear history, TSMG produces products with more consistent quality than the batch process. Several studies have investigated how various formulation and processing parameters influence granulation behavior and granule properties; however, there are still challenges that require a better mechanistic understanding. This review summarizes the current progress of TSMG while highlighting how various formulation and process parameters affect the physicochemical properties of granules. The challenges related to the process-induced physicochemical changes of drug substances are also discussed.
Asunto(s)
Excipientes/química , Preparaciones Farmacéuticas/química , Tecnología Farmacéutica , Formas de Dosificación , Composición de Medicamentos , Diseño de Equipo , Excipientes/normas , Preparaciones Farmacéuticas/normas , Control de Calidad , Tecnología Farmacéutica/instrumentación , Tecnología Farmacéutica/normasRESUMEN
Identification of Critical Quality Attributes (CQAs) and subsequent characterization in process development studies are the key elements of quality by design (QbD) for biopharmaceutical products. Since the inception of ICH Q8R2, several articles have been published on approaches to conducting CQA risk assessments as well as the application to process understanding. A survey was conducted by multiple companies participating in an International Consortium working group on the best practices for identifying CQAs with linkages to process characterization (PC) studies. The results indicate that the companies surveyed are using similar approaches/timing to identify CQAs during process development. Consensus was also observed among the companies surveyed with approaches to linkage of CQAs to process characterization studies leading to impact to control strategies and lifecycle management.
Asunto(s)
Benchmarking/métodos , Productos Biológicos/química , Química Farmacéutica/métodos , Industria Farmacéutica/métodos , Encuestas y Cuestionarios , Tecnología Farmacéutica/métodos , Benchmarking/normas , Benchmarking/estadística & datos numéricos , Productos Biológicos/normas , Productos Biológicos/uso terapéutico , Química Farmacéutica/normas , Química Farmacéutica/estadística & datos numéricos , Diseño de Fármacos , Industria Farmacéutica/normas , Industria Farmacéutica/estadística & datos numéricos , Humanos , Control de Calidad , Proyectos de Investigación , Medición de Riesgo/métodos , Medición de Riesgo/estadística & datos numéricos , Tecnología Farmacéutica/normas , Tecnología Farmacéutica/estadística & datos numéricosRESUMEN
Research emphases on extensive experimental studies and modeling efforts have been on the rise for the development of accurate predictive models of pharmaceutical unit operations and 'digital-twin' framework for continuous manufacturing lines. These exhaustive studies have been conducted at different process conditions to acquire comprehensive knowledge of effects of process parameters on the overall process dynamics. However, there still lacks a detailed understanding of material property effects of pharmaceutical powders on process operation. To address this issue, a discrete element modeling (DEM) approach combined with material calibration is applied for simulation of feeder unit to obtain particle-level insight into effects of material properties on feeder performance with focus on particle flow and powder mixing within the feeder unit. Bulk calibration is implemented to accurately represent powder material properties within the DEM framework. Different refill situations are simulated using DEM to observe powder mixing, measured at the outlet. Feeder DEM simulations are further applied to understand correlations of material properties on feeder operation. These studies provide a detailed physical insight and particle-scale information into the powder mechanics during powder feeding operation.